

6-81644

AMENDMENT TRANSMITTAL LETTER		APR-09 1999 PATENT & TRADEMARK OFFICE	ATTORNEY'S CHECK NO. 16715/CIP
Serial No. 08/902,692	Filing Date 7/30/97	Examiner Schwadron, R.	Group Art Unit 1644
INVENTION AUTOGENOUS LYMPHATIC FACTOR FOR MODIFICATION OF T AND B LYMPHOCYTE PARAMETERS			

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS:

Transmitted herewith is an amendment in the above-identified application.

- ☒ Small entity status of this application under 37 CFR 1.27 has been established by a verified statement previously submitted.
- ☐ A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.
- ☒ No additional fee is required.
- ☒ The fee has been calculated as shown below:

(1)		(2)		(3)	SMALL ENTITY		OR	OTHER THAN A SMALL ENTITY	
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDIT FEE		RATE	ADDIT FEE
TOTAL	34		48	0	x \$ 9 =	0		x \$18 =	0
INDEP	3		4	0	x \$39 =	0		x \$78 =	0
FIRST PRESENTATION OF MULTIPLE DEP CLAIM					\$130	0		\$260	0
					TOTAL ADDIT. FEE	0		OR TOTAL	0

* If the entry in Col 1 is less than the entry in Col 2 write "0" in Col 3
 ** If the Highest No Previously Paid For IN THIS SPACE is less than 20 enter "20"
 *** If the Highest No Previously Paid For IN THIS SPACE IS LESS THAN 3 ENTER "3"
 The Highest No Previously Paid For (Total or Indep) is the highest number found in the appropriate box in Col 1

- ☐ Please charge my Deposit Account No. 03-3840 in the amount of \$_____. A duplicate copy of this sheet is enclosed.
- ☐ A check in the amount of \$_____ to cover the filing fee is enclosed.
- ☐ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 03-3840. A duplicate copy of this sheet is enclosed.
- ☐ Any additional filing fees required under 37 CFR 1.16.
- ☐ Any patent application processing fees under 37 CFR 1.17

RECEIVED

APR 12 1999

MAIL ROOM
SERVICE CENTER

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed for the HON. COMMISSIONER OF PATENTS AND TRADEMARKS, WASHINGTON, D. C. 20231 on:

Respectfully submitted,

April 7, 1999
 Date of Deposit


Todd E. Albanesi
 Name of Applicant, Assignee or Registered Representative

Todd E. Albanesi
 Signature

April 7, 1999
 Date of Signature

Todd E. Albanesi
 Todd E. Albanesi, Reg. 36,426
 CRUTSINGER & BOOTH
 1601 Elm Street, Suite 1950
 Dallas, Texas 75201-4744
 (214) 220-0444; Fax (214) 220-0445

Attorneys for Applicants



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In response to Application of: William J. Rea, MD, et al
Serial No.: 08/902,692
Filed: July 30, 1997
For: **AUTOGENOUS LYMPHATIC FACTOR FOR
MODIFICATION OF T AND B LYMPHOCYTE PARAMETERS**

Attorney Docket: 16715/CIP
Art Group Unit: 1644
Examiner: Schwadron, R.

12/B
M. J. J
4/16/99

AMENDMENT

Honorable Commissioner of Patents
and Trademarks
Washington, D.C. 20231

Sir:

In response to the Office Action mailed February 12, 1999 and a short telephone interview on March 16, 1999, please amend the application as follows:

In the Title:

Please change the title to – Method Of Treating A Chemically Sensitive Individual –

In the Specification:

- ~~At page 1, line 13, please delete "normal".~~
- ~~At page 3, line 7, delete "normal".~~
- ~~At page 3, line 15, delete "normal".~~
- ~~At page 6, lines 9-10, delete "normal (non-cancerous or otherwise dysfunctional)".~~
- ~~At page 6, line 16, delete "normal".~~
- ~~At page 8, line 22, delete "normal".~~

In the Abstract of the Disclosure:

[Please delete the entire text of the abstract in favor of the following new text:]

– A method for treating a chemically sensitive individual is provided. The method includes the steps of: collecting a blood sample from the individual; isolating mixed T and B lymphocytes from the blood sample; propagating the isolated mixed T and B lymphocytes to obtain propagated lymphocytes; lysing the propagated lymphocytes to obtain a lysate; and administering the lysate to the individual. A therapeutic dose of the lysate can be determined by skin testing, and the dose can be